HOME  |   NEWSROOM

NEWS ROOM

OncoStem Diagnostics launches CanAssist-Breast: an innovative Breast cancer recurrence prediction test

OncoStem Diagnostics announces the launch of its flagship product - “CanAssist-Breast”, an accurate and cost-effective test to predict the risk of breast cancer recurrence in early stage hormone positive and Her2 negative Breast Cancer patients.   In India, about 150,000 patients are diagnosed with breast cancer every year, and this number is expected to double within the next decade. Currently, there are no affordable tests to predict the risk of cancer recurrence. As a result, the majority of....

About OncoStem Diagnostics, Published in ET

“Today in India over 90% of breast cancer patients go for chemotherapy to avoid recurrence however if you are a stage 1 cancer patient you might not have to go through chemo, our test helps determine that crucial decision,” Dr Manjiri Bakre, Founder of OncoStem told ET. The start up’s CanAssist-Breast test, Bakre claims, costs one fifth of what similar tests cost in US and Europe with less turnaround time. Typical tumour diagnostic tests roughly cost $4000 or RS 2.8 lakhs in US, Bakre says.    ....

OncoStem in ABSICON 2016

OncoStem Diagnostics participated in ABSICON 2016, a Breast Cancer focused surgical oncology meeting held from July 1st-3rd at Hotel ITC Gardenia, Bangalore. Dr. Manjiri Bakre gave an invited lecture on the development and validation of CanAssist-Breast and its utility in patients with Breast Cancer. OncoStem Diagnostics also had a booth at ABSICON 2016 showcasing CanAssist-Breast.         ABSICON 2016 is the 5th Annual Conference of the Association of Breast Surgeons of India. Theme of the....